National Bleeding Disorders Foundation/X
Aug 31, 2025, 09:45
Slow Uptake of Hemophilia Gene Therapies: Challenges in Access and Adoption
National Bleeding Disorders Foundation (NBDF) shared on X:
”A new forum piece in Research and Practice in Thrombosis and Haemostasis explores the complex factors at play, from long-term efficacy and safety questions to cost, access, and patient decision-making.
Read the full open-access article.”
A recent RPTH forum article examines why the uptake of hemophilia gene therapy remains modest, citing concerns over long-term efficacy and safety, high costs, access barriers, and competition from effective non-factor therapies.
Latest news in the field of bleeding disorders featured in Hemostasis Today.
-
Dec 8, 2025, 11:23Jorge Di Paola and Diane Krause Take Their Awards at ASH25
-
Dec 8, 2025, 11:08Andreas Tiede: This Will Change Hematology Forever
-
Dec 8, 2025, 09:39Asfand Yar Cheema Honored with Abstract Achievement Awards at ASH25
-
Dec 8, 2025, 09:27Ana Rita Rodrigues on the Impact of Post-Stroke Dysphagia
-
Dec 8, 2025, 09:19Sanam Loghavi and Shannon McWeeney at Joint Session on AI nad Hematology at ASH25
-
Dec 7, 2025, 18:43ASH25 Day 2: Don’t Miss The Highlights
-
Dec 7, 2025, 18:05Heghine Khachatryan Highlights a Patient-Friendly Breakthrough: Finger-Prick Micro-Sampling for Platelet Function
-
Dec 7, 2025, 17:01Abdul Mannan: How Do You Manage a Major Surgery When Blood Transfusion is Impossible?
-
Dec 7, 2025, 16:51Ahmed Bahi on Lina Merghani’s Critique of Early Withdrawal of Aspirin after PCI